Capricor rises after FDA asks for more data but no new trials for Duchenne therapy

Shares of drugmaker Capricor Therapeutics CAPR.O rise 6.4% to $25.90 premarket

Co says FDA has asked for additional documents to support its review of deramiocel, an experimental treatment for Duchenne muscular dystrophy, a muscle‑wasting disease

Co says it plans to submit the full late‑stage trial report in February to address FDA's questions

FDA did not request new trials or more patients, per co

Co's deramiocel aims to help preserve muscle and heart function

Late-stage trial showed improvements in strength and heart health - CAPR

As of last close, stock up ~109% over the past year